Literature DB >> 10899445

Childhood chronic inflammatory demyelinating polyneuropathy: clinical course and long-term outcome.

M M Ryan1, P J Grattan-Smith, P G Procopis, G Morgan, R A Ouvrier.   

Abstract

We reviewed the clinical history, electrophysiologic and pathologic findings, and response to therapy of 16 children with chronic inflammatory demyelinating polyneuropathy. The majority presented with lower limb weakness. Sensory loss was uncommon. The illness was monophasic in seven children, relapsing in six, and three had a slowly progressive course. All patients were treated with immunosuppressive agents. In 11, the initial treatment was prednisolone. All had at least a short-term response but five went on to develop a relapsing course. Intravenous immunoglobulin was the initial treatment in four patients. Three responded rapidly, with treatment being stopped after a maximum of 5 months. In resistant chronic inflammatory demyelinating neuropathy, in addition to prednisolone and immunoglobulin, plasma exchange, azathioprine, cyclosporine, methotrexate, cyclophosphamide and pulse methylprednisolone were tried at different times in different patients. On serial neurophysiologic testing slowing of nerve conduction persisted for long periods after clinical recovery. Follow-up was for an average of 10 years. When last seen 14 patients were asymptomatic, two having mild residual deficits. Childhood chronic inflammatory demyelinating neuropathy responds to conventional treatment and generally has a favourable long-term outcome.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10899445     DOI: 10.1016/s0960-8966(00)00119-x

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  15 in total

Review 1.  Therapeutic apheresis.

Authors:  J P Isbister
Journal:  Indian J Pediatr       Date:  2001-01       Impact factor: 1.967

Review 2.  Chronic inflammatory demyelinative polyneuropathy.

Authors:  Gérard Said
Journal:  J Neurol       Date:  2002-03       Impact factor: 4.849

3.  Pathogenesis and treatment of immune-mediated neuropathies.

Authors:  Helmar C Lehmann; Gerd Meyer Zu Horste; Bernd C Kieseier; Hans-Peter Hartung
Journal:  Ther Adv Neurol Disord       Date:  2009-07       Impact factor: 6.570

Review 4.  IVIG therapy in neurological disorders of childhood.

Authors:  Juan J Archelos; Franz Fazekas
Journal:  J Neurol       Date:  2006-09       Impact factor: 4.849

5.  Treatment of chronic inflammatory demyelinating polyradiculoneuropathy with methotrexate.

Authors:  D Fialho; Y-C Chan; D C Allen; M M Reilly; R A C Hughes
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-04       Impact factor: 10.154

Review 6.  Advances in the diagnosis, pathogenesis and treatment of CIDP.

Authors:  Marinos C Dalakas
Journal:  Nat Rev Neurol       Date:  2011-08-16       Impact factor: 42.937

7.  Chronic Inflammatory Demyelinating Polyneuropathy: A Case Series.

Authors:  Arunmozhimaran Elavarasi; Vinay Goyal; Venugopalan Vishnu; Mamta Bhushan Singh; Padma Srivastava
Journal:  Indian J Pediatr       Date:  2017-11-16       Impact factor: 1.967

Review 8.  Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Mohamed Mahdi-Rogers; Ruth Brassington; Angela A Gunn; Pieter A van Doorn; Richard Ac Hughes
Journal:  Cochrane Database Syst Rev       Date:  2017-05-08

9.  Clinical and pharmacological aspects of inflammatory demyelinating diseases in childhood: an update.

Authors:  Alberto Spalice; Pasquale Parisi; Laura Papetti; Francesco Nicita; Fabiana Ursitti; Francesca Del Balzo; Enrico Properzi; Alberto Verrotti; Martino Ruggieri; Paola Iannetti
Journal:  Curr Neuropharmacol       Date:  2010-06       Impact factor: 7.363

10.  Pediatric CIDP: Diagnosis and Management. A Single-Center Experience.

Authors:  Małgorzata Łukawska; Anna Potulska-Chromik; Marta Lipowska; Dorota Hoffman-Zacharska; Beata Olchowik; Magdalena Figlerowicz; Karolina Kanabus; Edyta Rosiak; Anna Kostera-Pruszczyk
Journal:  Front Neurol       Date:  2021-07-02       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.